Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
62.37
+1.27 (2.08%)
At close: Feb 27, 2026, 4:00 PM EST
62.25
-0.12 (-0.19%)
After-hours: Feb 27, 2026, 7:58 PM EST
BMY Revenue
In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%. Bristol-Myers Squibb Company had revenue of $12.50B in the quarter ending December 31, 2025, with 1.30% growth.
Revenue (ttm)
$48.19B
Revenue Growth
-0.22%
P/S Ratio
2.64
Revenue / Employee
$1,482,892
Employees
32,500
Market Cap
127.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| GSK plc | 43.97B |
BMY News
- 2 days ago - SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer - Business Wire
- 3 days ago - NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options - PRNewsWire
- 5 days ago - Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference - Business Wire
- 5 days ago - Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia - Business Wire
- 9 days ago - Bristol-Myers: I'm Buying Post Earnings - Seeking Alpha
- 9 days ago - Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength - Seeking Alpha
- 11 days ago - U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma - Business Wire
- 16 days ago - These 32 favorite stocks signal the bull market is running on fumes - Market Watch